HMP Market Access Insights (MAI) has been reporting on vertical payer integration since the inception of our primary payer research arm in 2022. Every year, we hear how these national players intend to further enhance their internal integration regarding business operations, policy decision making, and data sharing. However, this year we see a greater than normal ‘bump’ for what the future holds. In short, vertical payers anticipate a very high degree of integration within these critically important areas over the next few years (Figure).
Figure. Percentage of 2024 Vertical Payer Respondents Selecting “High” or “Full” Integration (N = 25).
Source: HMP Market Access Insights 2024 Payer Annual Oncology Trend Report.
We look forward to sharing additional insights later this summer when we release our full 2024 Payer Annual Trend Report, part of our suite of Oncology Customer Insights offerings!
Be sure to check out the other reports from HMP MAI:
In the interim, please feel free to reach out to Sara Stewart with any questions you may have!
As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.
Daniel BuchenbergerIn the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.
Lee BlansettBispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Chris Van Denburg